Tag: Angion

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Topline data expected in the second half of 2021 ST. GALLEN, Switzerland & UNIONDALE, NY–(BUSINESS WIRE)–Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion’s AKI-002-15 study, a phase-II trial of ANG-3777 in […]